Skip to main content
Equibles
BIXT logo

BIXT · Bioxytran, Inc · Metrics

Track BIXT — free

Use BIXT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BIXT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.02 +0.00 (+4.91%) At close · Oct 20
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$2.57M
Shares
114.70M
Volume · Oct 20 57.42K Avg daily vol (3M) 95.14K

BIXT metrics

57 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.02
Market cap
$2.57M

Price action

20 metrics
Price change (1W)
+4.9%
Price change (30D)
+16.9%
Price change (3M)
-2.9%
Price change (6M)
-35.4%
Price change (YTD)
-69.0%
Price change (1Y)
-65.2%
Trailing year
Price change (5Y)
+968.2%
52-week high
$0.09
52-week low
$0.02
Change from 52-week high
-73.9%
Change from 52-week low
+16.9%
Annualized volatility
118.6%
Annualized volatility (3M)
119.9%
Beta
-1.1
RSI (14D)
53.4
Price vs SMA 50
+4.7%
Price vs SMA 200
-34.8%
Avg volume (3M)
95,141
Relative volume
0.6
Average dollar volume
$2,123

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
114.70M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
14.4×
reciprocal yield 6.9%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-136.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
45.6%
Operating margin
-162.5%
Trailing 12 months
Net margin
-166.6%
Gross profit (TTM)
$83,521
Operating profit (TTM)
−$3.69M
Net income (TTM)
−$3.49M
Trailing 12 months
Diluted EPS (TTM)
$-0.03
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.00
Book value per share
$-0.02

Growth

11 metrics
Revenue growth YoY
-48.5%
Year over year
Net income growth YoY
-1,849.3%
Revenue (TTM)
$177,794
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+28.7%
Year over year · more shares
Revenue CAGR (3Y)
-11.5%
Revenue CAGR (5Y)
-9.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-1,048.0%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
-25.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$23,448
Total assets
$333,393
Total debt
$48,070

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$874,319
Capital expenditures (TTM)
—
R&D (TTM)
$482,958
SG&A (TTM)
$213,338
Stock compensation (TTM)
$193,089
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
33 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1445815 CUSIP 09075D102 Visit website Investor relations